Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to nutrient intake, stimulating insulin secretion and suppressing glucagon secretion. GLP-1 agents tirepazide supplier possess promising therapeutic effica